Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Neoplasm Metastasis 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1

Interventions

Doxorubicin 4Sunitinib 3Radiosurgery 3Everolimus 3pembrolizumab 2exemestane 2Tamoxifen 2Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Filgrastim 2Biopsy 2Bevacizumab 23-Iodobenzylguanidine 2tislelizumab 1surufatinib 1romidepsin 1regorafenib 1penpulimab 1pasireotide 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1lanreotide 1ganitumab 1folfirinox 1fludarabine phosphate 1epothilone B 1entrectinib 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × penpulimab × Endocrine × Clear all
NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Peking Union Medical College Hospital

Phase 2 Unknown
5 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡